Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study. 20. Februar 2020 Lüftner, D., Welslau, M., Liersch, R., Deryal, M., Brucker, C., Rauh, J., Welt, A., Zaiss, M., Houet, L., Vannier, C., Potthoff, K., Marschner, N., 2020. Oncol Res Treat 43 (suppl 1)(272), 14. Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study. Welt, A., Welslau, M., Lüftner, D., Deryal, M., Liersch, R., Sahlmann, J., Houet, L., Potthoff, K., Marschner, N., 2020. Oncol Res Treat 43 (suppl 1)(270),… Weiterlesen Reduction of severity of chemotherapy-induced peripheral neuropathy by OnLife®14.02.2020 Final results of the breast cancer cohort of the STEFANO trial. Zaiss, M., Uhlig, J., Zahn, M.-O., Decker, T., Lehmann, H., Harde, J., Hogrefe, C., Vannier, C., Marschner, N., 2020. Oncol Res Treat 43 (suppl 1)(405),… Weiterlesen